Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3501MR)

This product GTTS-WQ3501MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3501MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12811MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ5418MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ3320MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ8348MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ13960MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ5854MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ4308MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ5880MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW